In conclusion, our results indicate that the newly designed partial PPAR Ƴ synthetic derivative, in addition to its anti-hypoglycemic potential, reduces the severity of vascular damage induced due to T2D through upregulating expression of microRNA126-5p, p-AKT/p-Pi3k/p-PDK 1/p-mTOR, and eNOS. The gene discussed is AKT1; the disease is type 2 diabetes mellitus.